tbuckley/cabot-search huggingface dataset:
AB1122 Better Outcomes of Disease Activity in a Large Cohort of Rheumatoid Arthritis Patients Treated Under Treat to Target Recommendations
Authors: G. Saavedra-Martinez, L. Villarreal, P. Santos-Moreno, D. Gomez, J. Bello-Gualtero, V. Giraldo, P. Martinez, A. Sanchez, M. Sanchez, E. Uribe, M. Boon
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Treat to Target (T2T) strategy arises from the need to develop therapeutic targets and tools to achieve defined outcomes in rheumatoid arthritis (RA). <h3>Objectives</h3> The aim of this study was to describe global change in Disease Activity Score 28 (DAS28) using T2T strategy for a 24 month period in a large cohort of patients from a Colombian specialized in RA center. <h3>Methods</h3> A descriptive cross-sectional study was performed. Records of patients from specialized in RA center were reviewed; those patients were followed-up under T2T standards. Clinical follow-up was designed by the authors according to DAS28 as follows: every 3-5 weeks (DAS28 &gt;5.1), every 7-9 weeks (DAS28 ≥3.1 and ≤5.1), and every 11-13 weeks (DAS28 &lt;3.1). Tender joint count (TJC), swollen joint count (SJC) and DAS28 were measured on each visit. Therapy had to be adjusted with DAS28 &gt;3.2 unless patient9s conditions don9t permit it; we considered this follow-up type as implementation of a T2T strategy in patients with RA. We divided patients in four groups: remission (Rem), low disease activity (LDA), moderate disease activity (MDA) and severe disease activity (SDA) patients and the aim of the study was to look at what percentage of patients who were in moderate or severe disease activity reached a low disease activity or remission. Descriptive epidemiology was done, percentages and averages were calculated; the median of each variable was analyzed using t-Student assuming normality for DAS28 distribution and the level activity disease was analyzed using Pearson9s statistics. <h3>Results</h3> 1400 patients were included in this study, 1054 (75.2%) women and 346 (23.7%) men. Mean age 61 years. With regard to treatment it was found that 290 (20.7%) patients were treated with biologics, and 1110 (79.2%) patients with conventional therapy. It was found a global increase in the percentage of patients in remission (REM) and decrease in moderate and severe disease activity groups. The mean of DAS28 was 3.6 at the beginning and 24 months after was 2.6. At 24 months was observed an increase in percentage of patients in remission and a decrease in percentage of patients in MDA/SDA disease activity statistically significant. The difference of medians for each variable showed improvement with statistical significance (p&lt;0.00). <h3>Conclusions</h3> This study shows improvement of DAS28 and level of disease activity in a cohort of RA patients from a specialized center in Colombia treated under recommendations of T2T strategy; it was found a global increase in the percentage of patients in remission (REM) and decrease in moderate and severe disease activity groups. This revision shows the importance of T2T follow-up and treatment for this disease. <h3>Disclosure of Interest</h3> None declared
The Etiology, Pathology and Treatment of Diseases of the Hip-joint.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0167 MRP8/14 Serum Complexes as Predictor of Response to Biological Treatments in Rheumatoid Arthritis
Authors: I. Y. K. Choi, M. J. Herenius, C. A. Wijbrandts, R. M. Thurlings, J. Roth, D. Föll, D. M. Gerlag, P.-P. Tak, D. Holzinger
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Biological therapy has dramatically improved the treatment of rheumatoid arthritis (RA). One-third of patients however show a lack of clinical response to this treatment. The use of robust predictive markers of response to identify individuals who are likely to respond to biological treatments may provide guidance in optimizing treatment strategies and lead to lower costs. <h3>Objectives</h3> To test the ability of MRP8/14 serum complexes, a major granulocyte and monocyte protein associated with inflammation in patients with RA<sup>1</sup>, to differentiate between responders and non-responders to various biological treatments and to monitor disease activity in these RA patients. <h3>Methods</h3> 170 RA patients were treated with adalimumab, infliximab or rituximab and were categorized into responders (n= 123) and non-responders (n = 47) according to the European League Against Rheumatism (EULAR) response criteria. Serum concentrations of MRP8/14 complexes were measured at baseline, week 4 and week 16 and divided in low and high MRP8/14 serum complexes level groups based on the median level for each treatment group. Non-parametric tests were used to analyse the data. <h3>Results</h3> Before initiation of adalimumab, infliximab or rituximab treatment, responders showed significantly higher levels of MRP8/14 serum complexes compared to non-responders. (p=0.010, p=0.001 and p&lt;0.001, respectively). Logistic regression analysis showed that having a high level of MRP8/14 serum complexes at baseline increased the odds of being a responder by a factor of 3.3 till 55. MRP8/14 serum complexes levels decreased after 4 weeks with respectively 46% and 60% (respectively median delta changes Δ400;IQ 160-895 and 840;IQ170-1170) and 16 weeks with 61% and 68% (Δ730;IQ220-1120 and Δ970;IQ530-1830) of treatment in responders to adalimumab and infliximab, while MRP8/14 serum complexes levels were stable in non-responders. In patients treated with rituximab, MRP8/14 serum complexes decreased with 61% (Δ1670;IQ959.5-3520) after 16 weeks in responders (p = 0.0005) and increased with 89% (Δ960;IQ405-1135) after 16 weeks in non-responders to treatment (p = 0.0039). <h3>Conclusions</h3> MRP8/14 serum complexes can be used as a biomarker predictive of the response to biological therapy in RA patients. <h3>References</h3> Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. <i>Arthritis Res Ther</i> 2009;<b>11</b>:R39. <h3>Disclosure of Interest</h3> None Declared
The Promotion
Authors: William A. Hensel
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Irresponsible Authorship
Authors: WILLIAM D. GRANT
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 August 1986Irresponsible AuthorshipWILLIAM D. GRANT, Ed.D.WILLIAM D. GRANT, Ed.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-2-292_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Your recent article on authorship (1) fails to address adequately the issue of incomplete authorship. I contend that the omission of authors who had responsibility for critical content of a paper, instead of being a rare occurrence, is a rather common event in university medical settings. I have found it to be a typical abuse of senior research assistants and senior technical staff whose contributions range from important changes in study design, to development of analysis protocols, to literature analysis (as opposed to article gathering). Frequently, these persons are excluded on the basis of their lack of...Reference1. HUTH E. Irresponsible authorship and wasteful publication. Ann Intern Med. 1986;104:257-9. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1986Volume 105, Issue 2Page: 292-292 Issue Published: 1 August 1986 PDF DownloadLoading ...
Syncope
Authors: Pradyot Saklani, Andrew Krahn, George Klein
Journal: Circulation (2013)

autonomic failure.Orthostatic hypotension may also trigger reflex mediated syncope. 18 Cardiac SyncopeCardiac syncope is most often arrhythmic.Syncope during tachycardia is related to rate but modulated by the specific arrhythmia (supraventricular/ventricular), preload conditions, posture, left ventricular function, and adequacy of vascular adaptation. 19Sinus node dysfunction or AV block may cause bradycardia directly or after tachycardia termination (tachybrady).Syncope attributable to sinus node dysfunction or AV block is often related to vascular adaptation to sudden rate drop, because most patients with fixed bradycardia have normal or elevated systolic blood pressure.Tachycardia may trigger vasovagal syncope. 20Bradycardia may prolong the QT interval in susceptible individuals and trigger torsade de pointes.Fixed or dynamic mechanical obstruction to cardiac output especially with exertion is less frequent. CirculationMarch 26, 2013 events. 22In essence, patients with vasovagal syncope often have clustering of events separated by long periods of quiescence.
Book: Pandora's Poison: Chlorine, Health and a New Environmental Strategy
Authors: D. Campbell
Journal: BMJ (2001)

MIT Press, £23.50, pp 596 ISBN 0 262 20124 0 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> Since the publication of Rachel Carson's Silent Spring in 1962, the role of organochlorines in infertility, immune suppression, cancer, and developmental disorders in humans and wildlife has been argued among environmentalists, epidemiologists, and toxicologists. These conflicts were accentuated by the controversy surrounding the land disposal of waste at Love Canal, Niagara Falls, in the United States. Some of the debate has centred around the role of risk assessment. Decision makers want estimates … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
421. A Multidrug Resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
Authors: Julien Valton, Valerie Guyot, Alan Marechal, Jean-Marie Filhol, Alexandre Juillerat, Aymeric Duclert, Philippe Duchateau, Laurent Poirot
Journal: Molecular Therapy (2015)

The adoptive transfer of CAR T cell represents a highly promising strategy to fight against multiple cancers. The clinical outcome of such therapies is intimately linked to the ability of effector cells to engraft, proliferate and specifically kill tumor cells within patients. When allogeneic CAR T cell infusion is considered, host versus graft and graft versus host reactions must be avoided to prevent rejection of adoptively transferred cells, host tissue damages and to elicit significant antitumoral outcome. This work proposes to address these three requirements through the development of multidrug resistant TCRαB-deficient CAR T cells. We demonstrate that these engineered T cells displayed efficient antitumor activity and proliferated in the presence of drugs, currently used in clinic as preconditioning lymphodepleting regimens. The absence of TCRαB at their cell surface along with their drug-resistance properties could prevent their alloreactivity and enable them to resist to lymphodepleting regimens that may be required to avoid their ablation via HvG reaction. By providing a basic frame work to develop a universal T cell compatible with allogeneic adoptive transfer, this work is laying the foundation stone of the large scale utilization of CAR T cell immunotherapies.
The Protection of Motherhood.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early and Long-Term Results of a Valve-Sparing Operation for Marfan Syndrome
Authors: Emma J. Birks, Carole Webb, Anne Child, Rosemary Radley-Smith, Magdi H. Yacoub
Journal: Circulation (1999)

Background —We have previously described the experience, rationale, and development of a valve preserving technique, but its role in patients with Marfan syndrome has not previously been defined. Here, we attempt to determine the early and long-term results, timing, and determinants of outcome of this operation in patients with Marfan syndrome. Methods and Results —Since 1979, 82 patients (73.2% of all patients with Marfan syndrome undergoing resection of aneurysm of the ascending aorta) were operated on using this technique. Ages ranged from 2 to 69 years (mean, 33.9 years). In all, there were 4 early deaths (4.9%), 2 with acute dissection and 2 with chronic aneurysm operated on as emergencies. There were no early deaths in 67 patients operated on electively. Actuarial survival for patients operated for chronic aneurysm was 94.2%, 94.2%, and 94.2% at 1, 5, and 10 years, respectively; that for acute dissection was 72.7%, 63.6%, and 63.6%; and that for chronic dissection was 100%, 85.7%, and 75.0%. The probability of needing reoperation was 5.7%, 17.3%, and 17.3% at 1, 5, and 10 years. There were no instances of infective endocarditis or thromboembolic complications except in 2 patients operated on early in the series who had cusp extension. At the end of the follow-up, trivial or no aortic regurgitation was demonstrated in 33.3%, mild in 45.6%, moderate in 21.1%, and severe in 0. Conclusions —Valve-sparing operations are feasible in most patients with Marfan syndrome; they are applicable to patients with both dissection and chronic aneurysm. The early and long-term results are encouraging. Results are better in the absence of dissection, and prophylactic operation is warranted in some cases.
Hints to the Young Practitioner.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mycobacterium tuberculosis Transmission in a Newborn Nursery and Maternity Ward--New York City, 2003
Journal: JAMA (2006)

Evaluating young children recently exposed to airborne Mycobacterium tuberculosis is a public health priority. If infected, children aged <2 years are at high risk for severe tuberculosis (TB) disease (e.g., TB meningitis). In December 2003, infectious pulmonary TB disease was diagnosed in a foreign-born nurse working in the newborn nursery and maternity ward of a New York City hospital (hospital A); the nurse had declined treatment for latent TB infection (LTBI) after testing positive 11 years earlier. An investigation including medical evaluation of contacts in the nursery and maternity ward was conducted by the Bureau of TB Control (BTBC) at the New York City Department of Health and Mental Hygiene, hospital A, and CDC. This report summarizes the results of that investigation, which determined that approximately 1,500 patients had been exposed to the nurse but the majority could not be located for evaluation. Among those who were tested, four infants had positive tuberculin skin test (TST) results, likely attributable to recent transmission of M. tuberculosis. The findings emphasize the difficulty of conducting contact investigations in certain settings and the importance of effective LTBI testing and treatment programs for health-care workers (HCWs) to prevent TB disease and subsequent health-care--associated transmission.
Poetry
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEW
Authors: L. R. KLEINBERG
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article BOOK REVIEW Get access Radiation Oncology: Technology and Biology Peter M. Mauch , Jay S. Loeffler , eds. Philadelphia : Saunders , 1994 . 594 pp., illus. $110. ISBN 0-7216-6724-4 LAWRENCE R. KLEINBERG, M.D LAWRENCE R. KLEINBERG, M.D Division of Radiation Oncology The Johns Hopkins Oncology Center600 North Wolfe St. Baltimore, MD 21287–8922 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 10, 17 May 1995, Pages 764–765, https://doi.org/10.1093/jnci/87.10.764 Published: 17 May 1995
A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.
Authors: Hatem Hussein Soliman, Susan E. Minton, Roohi Ismail-Khan, Hyo S. Han, William Janssen, Nicholas N. Vahanian, Charles J. Link, Howard Streicher, Daniel Sullivan, Scott Joseph Antonia
Journal: Journal of Clinical Oncology (2014)

TPS3125 Background: Indeolamine 2,3 dioxygenase (IDO) is an inducible tryptophan-catabolizing enzyme that downregulates the immune system. Many tumor cell types overexpress IDO to avoid elimination by infiltrating cytotoxic T cells. Indoximod (1-methyl-D-tryptophan/ D1MT) is an IDO pathway inhibitor. Published preclinical data suggests that blockade of IDO with indoximod enhances the immunologic response to dendritic cell (DC) vaccines. Ad.p53 is an adenovirus used for generating DC vaccines directed against p53 epitopes. Ad.p53 when given to previously treated SCLC patients significantly increased their response rate to subsequent chemotherapy. Data showing a similar trend for enhanced response to subsequent chemotherapy was presented in breast cancer patients who were treated in the phase I trial using Ad.p53DC and indoximod. The primary endpoint in phase II is the response rate of indoximod +Ad.p53 in metastatic breast cancer patients. Secondary endpoints include safety, PFS, OS, and immunologic correlates. Methods: This Phase 2 study uses a single arm, Simon two stage design. Patients with measurable, metastatic breast cancer, <3 lines of prior chemotherapy in metastatic setting, p53 immunohistochemistry >5% in archival tumor specimen, ECOG 0-2, no autoimmune disease are eligible. Study treatment consists of 1600mg PO BID of indoximod given continuously along with up to 6 fixed doses of Ad.p53DC SQ vaccinations q2weeks. First stage of accrual is 12 patients with one response required for progression into the second stage of 25 additional patients. The study design is based on the alternative hypothesis of a 20% response rate, with 90% power to detect this level of activity with a significance of .09 (assuming a total of 4 responses out of 37 are observed). Accrual to the first stage of this trial is completed and the study remains open with some of the patients still undergoing study treatment. Clinical trial information: NCT01042535.